Fat cells cannot maintain themselves without it
For decades, a protein called HSL was understood as a simple key that unlocks stored fat for the body to burn — a clean, settled story in the science of metabolism. But researchers at the University of Toulouse have discovered that HSL lives a double life, operating not only on the surface of fat droplets but deep inside the cell nucleus, where it quietly governs the health of fat tissue itself. This hidden role explains a long-standing paradox: why people without HSL waste away rather than grow heavy, and why obesity and its apparent opposite may share the same broken machinery. The discovery invites medicine to stop counting fat and start asking whether fat is well.
- A fifty-year-old scientific consensus has been overturned: HSL is not merely a fat-releasing enzyme but a dual-function protein whose nuclear role has gone entirely unnoticed until now.
- The paradox that triggered the investigation is stark — people and mice born without HSL lose fat tissue rather than accumulate it, developing lipodystrophy, a condition that carries the same metabolic dangers as obesity despite looking like its opposite.
- Inside the fat cell's nucleus, HSL partners with other proteins to regulate the genes that keep adipose tissue alive and functional, a maintenance role that collapses entirely when the protein is absent.
- In obese mice, HSL is found lingering in the nucleus at abnormally high levels, suggesting its carefully timed movement between locations has broken down — the protein is in the wrong place at the wrong time.
- With roughly two and a half billion people affected by obesity worldwide, this discovery points toward an entirely new class of treatments: not reducing how much fat the body stores, but restoring the health of the fat tissue itself.
For more than half a century, HSL was cast as a straightforward player in the body's energy story — a protein that sits on fat droplets and, when adrenaline signals the need, releases stored fat into the bloodstream. It was a clean narrative. Then a team led by Dominique Langin at the University of Toulouse's I2MC institute found that HSL is doing something far more complex, and the discovery is forcing a fundamental rethink of obesity and metabolic disease.
The puzzle began with a paradox. If HSL is the key that unlocks stored fat, people born without it should accumulate weight, unable to access their energy reserves. Instead, they lose fat. Both mice engineered without HSL and humans carrying mutations in the gene develop lipodystrophy — abnormally low fat tissue. Something deeper than fat release is broken.
What makes this more striking is that lipodystrophy and obesity, though apparent opposites, share troubling common ground. In both conditions, fat cells malfunction, and both carry similar consequences: disrupted glucose control, elevated cardiovascular risk, and cascading complications. The problem is not the quantity of fat, but the health of the fat itself.
Langin's team found HSL in two distinct locations inside the fat cell. The first was expected: on lipid droplets, performing its known role. The second was not. HSL also resides in the nucleus of adipocytes, where it associates with other proteins to regulate gene activity and maintain the proper functioning of fat tissue. Co-author Jérémy Dufau describes this nuclear presence as part of a program that keeps adipose tissue healthy and correctly sized.
This nuclear role is not static. Adrenaline — the same hormone that triggers fat release — also signals HSL to exit the nucleus during fasting. But in obese mice, HSL lingers there at higher-than-normal levels, suggesting the protein's carefully balanced movement has gone awry. Without HSL entirely, fat cells cannot regulate the genes that sustain them, and the tissue withers.
The implications reach far. In France alone, one in two adults carries excess weight. Globally, around two and a half billion people are affected by obesity — a gateway to diabetes, heart disease, and shortened lives. For decades, research has focused on how much fat people store. This discovery suggests the real question may be whether that fat is healthy — and that restoring HSL's nuclear function could open a therapeutic path no one has yet attempted.
For more than half a century, scientists have understood HSL as a straightforward actor in the body's energy story: a protein that sits on fat droplets and, when hormones like adrenaline give the signal, releases stored fat into the bloodstream for organs to burn. It was a clean narrative. But a team led by Dominique Langin at the University of Toulouse's I2MC institute has discovered that HSL is doing something far more complex—and that discovery is forcing researchers to rethink what they thought they knew about obesity and metabolic disease.
The surprise began with a puzzle. If HSL is the key that unlocks stored fat, then people born without a functioning HSL gene should accumulate fat, unable to access their energy reserves. Logic suggests they would gain weight. Instead, they lose it. Mice engineered without HSL, and humans carrying mutations in the HSL gene, develop lipodystrophy—a condition of abnormally low fat tissue. The body, it turns out, does not simply store fat when HSL is absent. Something else is broken.
What makes this finding even more striking is that lipodystrophy and obesity, though they appear to be opposite conditions, share a troubling common ground. In both cases, fat cells malfunction. Both conditions carry similar metabolic consequences: disrupted glucose control, increased cardiovascular risk, and a cascade of complications that can degrade quality of life. The problem is not the amount of fat, but the health of the fat itself.
To understand why, Langin's team looked inside the fat cell itself—not just at its surface. They found HSL in two places. The first location was expected: on the lipid droplets, doing the work scientists have known about for decades. But the second location was not. HSL also resides in the nucleus of adipocytes, the cell's control center, where it associates with other proteins to regulate gene activity. There, according to co-author Jérémy Dufau, HSL participates in a program that maintains the right amount of fat tissue and keeps fat cells functioning properly.
The researchers discovered that this nuclear presence is not static. Adrenaline, the same hormone that triggers HSL to release fat from droplets, also signals HSL to leave the nucleus. This happens during fasting, when the body needs energy. But in obese mice, HSL lingers in the nucleus at higher levels than normal, suggesting that this carefully balanced movement has gone awry in disease. The protein is not where it should be, when it should be there.
This dual role—fat mobilizer on the surface, tissue maintainer in the nucleus—explains the lipodystrophy mystery. Without HSL, fat cells cannot maintain themselves. They cannot regulate the genes that keep adipose tissue healthy. The tissue withers. But it also opens a new window onto obesity itself. If HSL's nuclear function is disrupted in obese individuals, then restoring that balance might offer a path toward treatment that has never been available before.
The stakes are substantial. In France alone, one in two adults carries excess weight or obesity. Globally, approximately two and a half billion people are affected. Obesity is not merely a cosmetic concern; it is a gateway to diabetes, heart disease, and a shortened lifespan. For decades, obesity research has focused on the amount of fat people store. This discovery suggests the real problem may be the health of the fat itself—and that fixing it might require a completely different approach than anyone has tried.
Notable Quotes
HSL has been known since the 1960s as a fat-mobilizing enzyme. But we now know that it also plays an essential role in the nucleus of adipocytes, where it helps maintain healthy adipose tissue.— Dominique Langin, University of Toulouse
In the nucleus of adipocytes, HSL is able to associate with many other proteins and take part in a program that maintains an optimal amount of adipose tissue and keeps adipocytes healthy.— Jérémy Dufau, co-author of the study
The Hearth Conversation Another angle on the story
So for sixty years, scientists thought HSL was just a fat-release switch. What made them look deeper?
They couldn't explain why people without HSL actually lose fat instead of gaining it. That contradiction forced them to ask what else HSL might be doing.
And they found it in the nucleus—the control room of the cell. How does a protein end up in two completely different places?
It moves. Adrenaline tells HSL to leave the nucleus and go to the fat droplets when energy is needed. In healthy people, that balance works. In obese people, HSL gets stuck in the nucleus.
So obesity isn't just about storing too much fat. It's about fat cells that can't maintain themselves.
Exactly. Lipodystrophy and obesity look opposite, but they're both diseases of broken fat tissue. The amount matters less than the health.
Does this mean we've been treating obesity wrong all along?
Not wrong, exactly. But incomplete. If you can't fix how fat cells regulate themselves, you're only treating the symptom, not the disease.
What happens next? How do researchers use this?
They'll likely try to restore HSL's nuclear function in obese patients—essentially teaching the protein to do its maintenance work again. That's never been possible before.